On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release.

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

The esketamine nasal spray – sold as Spravato by Johnson & Johnson – is the first new class of depression drug subsidised by the Pharmaceutical Benefits Scheme in more than 30 years.